Hashtag
The Times

First Patient Dosed in QBiotics MSD Clinical Trial Collaboration for Unresectable Melanoma

First Patient Dosed in QBiotics MSD Clinical Trial Collaboration for Unresectable Melanoma
  • First patient dosed with QBiotics' lead oncology molecule tigilanol tiglate in combination with KEYTRUDA® (pembrolizumab) in a clinical trial collaboration with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA)
  • The Phase Ib/IIa study will test the safety, optimal dose and tumour response of the combination in patients with...

Read more: First Patient Dosed in QBiotics MSD Clinical Trial Collaboration for Unresectable Melanoma

Health & Wellness

Looking After a Hearing Aid: The Small Daily Habits That Matter

Hashtag.net.au - avatar Hashtag.net.au

A hearing aid is a small electronic device worn close to skin, sweat and earwax, and it needs regular care to keep working as it should. Most of that care is simple and takes only a minute or two, b...

What to Look for When Choosing a Dental Clinic Melbourne Patients Can Rely On

Hashtag.net.au - avatar Hashtag.net.au

Look at the Range of Dental Care Available Choosing a dental practice is easier when patients can access different types of care in one place. A dental clinic Melbourne patients visit may provide gen...

What Do Clinical Teams Need from Their Surgical Supply Partners?

Hashtag.net.au - avatar Hashtag.net.au

In clinical settings, surgical supply partners aren’t just vendors. They sit quietly behind the scenes of operating lists, specialist consultations, treatment rooms and recovery workflows. When they...

hacklink esim usazlibraryzlibraryz-libraryFanatikbetJojobetcasinolevantcasinolevantcasinolevantcasinolevantcasinolevantcasinolevantcasinolevantcasinolevanttaraftariumjojobethacklink panelmarsbahisJojobetnot on gamestopuk casinos not on gamstopbahis casino siteleriataşehir escortanadolu escortkadıköy escort